STAT+: A conflict of interest behind the warning on Apellis’s eye drug? The optics are not good
The eye disease physician in charge of a committee that flagged a rare but severe…
Category: STAT+
.jpg)
STAT+: Pharmalittle: House Dems push new bill for Medicare drug negotiations; WHO leaves obesity drugs off essential medicines list
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: VC firm starts a new synthetic biology incubator, headed by a former Broad Institute scientist
Venture capital firm RA Capital is starting a new incubator, setting the stage for the…
STAT+: Senate panel advances PBM reform — but sidesteps anything controversial
WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to…
STAT+: UHS finance chief said company favors patients whose insurance pays more
The country’s largest private psychiatric hospital operator cherry picks patients whose insurance will pay more,…
STAT+: European Commission accelerates phasing out animal testing, but stops short of a ban
After months of deliberation, the European Commission has agreed to accelerate the phasing out of…
STAT+: Democrats decry a new health package as too easy on private equity
WASHINGTON — A rift between Democrats and Republicans over health care transparency was on full display…
STAT+: Democrats already want to expand Medicare’s drug price negotiation
WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats…
STAT+: Medical device maker Teleflex to acquire urology company Palette Life Sciences for $600 million
Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate…
STAT+: FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls
One of the largest compound pharmacy operations in the U.S. recently recalled a slew of…
STAT+: Pharmalittle: State Medicaid programs seek discounts for Wegovy; congressional PBM bills work around the fringes
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do
WASHINGTON — Lawmakers in Congress generally agree that there’s something very broken with the way America…
STAT+: South Africa faces court hearing over opaque Covid-19 vaccine contracts
A hearing began in a South Africa court on Tuesday to determine whether the government…
STAT+: Truvian presents data for its desktop blood-testing device in a field still in Theranos’s shadow
SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday…
STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Biogen says it will cut costs by $700 million, slash 1,000 jobs
Biogen announced a new round of cost cuts Tuesday, saying that it plans to save…
.jpg)
STAT+: Drug from Stoke shows lower activity against childhood epilepsy, prompting search for better dose
Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a…
As Alzheimer’s drugs hit the market, the race for early detection blood tests heats up
With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is…
STAT+: IQVIA built a health data empire to target drug ads. Now it’s the focus of an FTC lawsuit
The health data giant IQVIA became a dominant force by gobbling up its rivals. Over…
STAT+: Key House panel proposes lowering out-of-pocket drug costs in Medicare
WASHINGTON — A key House committee announced their own plans to increase health care transparency…
STAT+: Lawsuit says Cigna illegally denies claims in bulk, sticking patients with unexpected bills
A new lawsuit accuses Cigna of using an algorithm to automatically deny claims in bulk…
STAT+: Pharmalittle: Three big drugmakers spent less on lobbying after leaving PhRMA; EMA reviews CRO over data concerns
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Rise in cancer among younger people worries and puzzles doctors
When both the nurse and the doctor broke down in tears as they delivered the news,…
STAT+: Roche’s $3 billion Alnylam deal shows drug firms are interested in long-acting heart drugs
Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment,…
STAT+: A new lobby shop looks to remind Congress about NIH’s translational research arm
WASHINGTON — Christopher Austin was the first director of a then-tiny National Institutes of Health…
STAT+: Lobbying spending dropped for companies that departed PhRMA
WASHINGTON — The three companies that recently left PhRMA all spent less on lobbying following…
STAT+: Pfizer says most tornado damage at key plant hit warehouse, but finished drugs also impacted
Pfizer says a tornado that ripped through a key manufacturing plant in North Carolina does…
STAT+: Major pharma companies call on their suppliers to reduce carbon footprints
As anxiety mounts over climate change, seven of the world’s largest drugmakers urged dozens of…
STAT+: FDA official pushes for a dedicated emerging pathogens team to prepare for the next pandemic
WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff…
STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’
In the latest melee over the safety of prescription medicines, the European Medicines Agency is…
STAT+: Pharmalittle: Sanders wants to replace drug patents with prizes for innovation; FDA approves an anthrax vaccine
And so, another working week will soon draw to a close. Not a moment too…
STAT+: European regulatory panel weighs against approval of Mirati’s KRAS-targeted lung cancer drug
A European regulatory panel reviewing a lung cancer drug made by Mirati Therapeutics has recommended…
STAT+: Extensive review finds private equity owners jack up the cost of medical care
Private equity firms are rapidly buying their way into the U.S. health care system, and…
STAT+: Bernie Sanders wants to replace drug patents with prizes for breakthrough medicines
WASHINGTON — Sen. Bernie Sanders (I-Vt.) will finally get a study of his proposal to…
STAT+: Damages from tornado at Pfizer plant could compound challenges of drug shortages
The tornado that struck parts of North Carolina on Wednesday not only damaged the immediate…
STAT+: Pharmalittle: Health care mergers facing tougher antitrust scrutiny; tornado hits Pfizer plant and more shortages may result
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: FTC plans to reverse years of policy statements supporting pharmacy benefit managers
The U.S. Federal Trade Commission is reversing years of prior advocacy in support of pharmacy…
STAT+: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change
WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer…
STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers
Health care companies trying to merge can expect tougher policing from the top federal antitrust…
STAT+: Stanford president’s departure begs the question: Who takes the credit — or blame — in team science?
The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities…
STAT+: House committee probes FDA inspections of pharma plants in China and India
A Congressional committee is demanding the U.S. Food and Drug Administration provide detailed information about…
STAT+: Pharmalittle: J&J is third drugmaker to sue over Medicare negotiations; Teva faces trial over Medicare kickbacks
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: States increasingly look to regulate hospital facility fees
Unexpected “facility fees” charged by hospitals have become a growing source of rage for patients,…
STAT+: App developer Twill hunts for pharma partner to market its digital depression treatment
In another sign of the business headwinds facing prescription mental health apps, developer Twill will…
STAT+: To get better heart data from wearables, researchers train AI to separate the signal from the noise
As wearable health devices grow more popular in the U.S., there’s a growing opportunity to…
STAT+: Bernie Sanders adds three drug shortage policies to pandemic preparedness bill
WASHINGTON — Senate health committee Chair Bernie Sanders added three drug shortage measures to a…
STAT+: At Orexo, a ‘turning point’ for everything but digital health
Most everything is looking up for Orexo, the company reported on its second quarter earnings…
STAT+: Johnson & Johnson sues to stop Medicare negotiation
WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the…
STAT+: ‘Doctors need to get on top of this’: GPT-4 displays bias in medical tasks
Diagnosis is an especially tantalizing application for generative AI: Even when given tough cases that…
STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group…